Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG) - Takeaway - MDSpire
Clinical Guidelines

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)

This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent).

  • April 24, 2026

  • 7 min

Share

  • 1

    Phase III trial comparing gemcitabine with BCG for recurrent bladder cancer.

  • 2

    Led by Dr. Andres Correa.

  • 3

    Patients must have high-grade urothelial carcinoma.

  • 4

    Eligibility includes documented NMIBC history and treatment criteria.

  • 5

    Objective is to evaluate tumor response to combination therapy.

  • 6

    Exclusion of muscle-invasive disease and BCG intolerance is critical.

  • 7

    Requires pre-study imaging to confirm disease status.

  • 8

    Participants must not be pregnant or nursing.

Original Source(s)

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)

  • April 24, 2026

Related Content

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...

Ulrich Steidl, MD, PhD, Named Director of Montefiore Einstein Comprehensive Cancer Center

An international leader in blood cancer and stem cell research has been named Director of the Montefiore Einstein Comprehensive Cancer Center and Vice President of Cancer Medicine at Montefiore Einste...

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individ...